Abbott Launches New Delivery System to Improve Pain Treatment for CRPS Patients

Abbott has introduced a next-generation delivery system for its Proclaim™ Dorsal Root Ganglion (DRG) neurostimulation device, aimed at improving the precision and ease of electrode placement during implantations. The system is specifically designed to treat complex regional pain syndrome (CRPS) Types 1 and 2 of the lower limbs—conditions considered among the most painful in the world.

The Proclaim DRG system targets the dorsal root ganglion, a nerve cluster along the spine responsible for transmitting pain signals. The new delivery system enhances maneuverability and durability, allowing physicians to perform the implant procedure more efficiently and potentially broadening access to this advanced treatment.

Clinical data show significant pain relief for users, with 81% average reduction in pain intensity. The improved design is expected to make the procedure more accessible for physicians and increase patient access to DRG therapy.

Abbott emphasized that DRG stimulation provides better outcomes than traditional spinal cord stimulation for CRPS. This advancement underlines Abbott’s continued commitment to refining neuromodulation therapies to help people with chronic pain live fuller lives.

For safety information, visit: [Abbott DRG System Safety](https://bit.ly/3SheU6s).